Paul Ashton

Before co-founding Inflammasome Therapeutics, Dr. Ashton was CEO of pSivida Corp (PSDV). During his time with the company, it reincorporated into the U.S., established its primary listing on NASDAQ, had one of its licensed products (ILUVIEN®) obtain FDA and EU approval and developed another product (Yutiq®) through the successful completion of the first Phase III study. Dr. Ashton is the Inventor/Developer of 4 FDA-approved products (Yutiq for posterior uveitis, ILUVIEN for DME, Retisert® for posterior uveitis and Vitrasert® for CMV retinitis.